OXiGENE promotes senior executive
This article was originally published in Scrip
Executive Summary
OXiGENE (Sweden), a clinical-stage biopharmaceutical company developing therapeutics to treat cancer and eye diseases, has promoted John Kollins to chief operating officer. Mr Kollins, who most recently served as the company's senior vice-president and chief business officer, will continue to lead the company's business and corporate development initiatives, and in addition will assume responsibility for the company's operations.